

# CITATION REPORT

List of articles citing

**Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension**

**DOI: 10.1016/j.clinthera.2011.06.008**  
**Clinical Therapeutics, 2011, 33, 993-1004.**

**Source:** <https://exaly.com/paper-pdf/51152920/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
27	ADMET considerations for phosphodiesterase-5 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 1231-45	5.5	12
26	Tadalafil and pulmonary arterial hypertension. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 257	3.5	
25	A novel combinatorial biocatalytic approach for producing antibacterial compounds effective against <i>Mycobacterium tuberculosis</i> (TB). <i>Applied Microbiology and Biotechnology</i> , <b>2013</b> , 97, 7151-63	5.7	5
24	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 1193-205	5.5	19
23	Pediatric pulmonary arterial hypertension. <i>Current Hypertension Reports</i> , <b>2013</b> , 15, 606-13	4.7	4
22	Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2013</b> , 7, 39-49	4.9	13
21	Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension. <i>Hypertension</i> , <b>2013</b> , 61, 585-92	8.5	24
20	Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension. <i>Pediatric Cardiology</i> , <b>2014</b> , 35, 699-704	2.1	23
19	Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension. <i>Veterinary Journal</i> , <b>2014</b> , 202, 334-9	2.5	8
18	Effects of tadalafil administration on plasma markers of exercise-induced muscle damage, IL6 and antioxidant status capacity. <i>European Journal of Applied Physiology</i> , <b>2015</b> , 115, 531-9	3.4	20
17	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 834-44	59.2	618
16	Solubility of Tadalafil in Pharmaceutical Solvent Mixtures at 298.2K. <i>Chemical Engineering Communications</i> , <b>2015</b> , 202, 1522-1527	2.2	3
15	Drugs for Treatment of Erectile Dysfunction. <b>2016</b> , 783-800		
14	Effect of Tadalafil on Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation. <i>Pediatric Cardiology</i> , <b>2016</b> , 37, 55-61	2.1	13
13	Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2017</b> , 25, 254-259 <sup>1.8</sup>		7
12	Beneficial effects of bile acid receptor agonists in pulmonary disease models. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 1215-1228	5.9	14
11	Improving tadalafil dissolution via surfactant-enriched tablets approach: Statistical optimization, characterization, and pharmacokinetic assessment. <i>Journal of Drug Delivery Science and Technology</i> , <b>2017</b> , 41, 197-205	4.5	4

10	Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2017</b> , 165, 277-292	5.1	18
9	Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model. <i>Journal of Endocrinological Investigation</i> , <b>2019</b> , 42, 951-965	5.2	5
8	Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol. <i>American Journal of Cardiovascular Drugs</i> , <b>2019</b> , 19, 99-105	4	5
7	Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study. <i>Journal of Veterinary Cardiology</i> , <b>2019</b> , 24, 7-19	1.9	4
6	A focus on riociguat in the treatment of pulmonary arterial hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2019</b> , 125, 202-214	3.1	8
5	Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors. <i>ACS Chemical Neuroscience</i> , <b>2020</b> , 11, 1058-1071	5.7	3
4	In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. <i>International Journal of Nanomedicine</i> , <b>2021</b> , 16, 1221-1229	7.3	3
3	Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile. <i>Molecules</i> , <b>2021</b> , 26,	4.8	4
2	Enhanced Dissolution Rate of Tadalafil Nanoparticles Prepared by Sonoprecipitation Technique: Optimization and Physicochemical Investigation. <i>Iranian Journal of Pharmaceutical Research</i> , <b>2017</b> , 16, 1335-1348	1.1	3
1	Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	1